About Us

We are a healthcare company focused on delivering innovative and accessible solutions with quality at the core — partnering globally to build a reliable, future-ready ecosystem.

Explore ProductsDownload Brochure
58+
Countries served
125 MT
Pellet capacity / month
127+
Registered products

Who we are

Rraynex is an integrated pharmaceutical manufacturer combining API synthesis, intermediates and multi-particulate finished-dosage production under robust quality systems. Since our founding, we have emphasised regulatory readiness, process validation and scientific rigor — enabling partners to move efficiently from development to commercial supply.

Our capabilities include formulation development, pilot-to-commercial scale manufacturing, stability programs and dossier support (DMF/COA). By controlling critical process steps within the same organisation, we reduce variability, improve traceability and accelerate global registrations.

What we have achieved

In a short timeline, we have scaled production, expanded our registered portfolio and implemented international quality standards. Key milestones include vertical integration (2023), pellet GMP unit commissioning (2024), and WHO-GMP certification with validated capacities (2025).

We deliver targeted technical support — stability datasets, validated methods and DMF-ready summaries — so customers can rely on documented product performance across diverse markets.

Milestones & Growth

2021 — Company foundation & quality-first build

Founded with a clear mission to make high-quality medicines accessible, Rraynex invested early in laboratory infrastructure, quality management systems and leadership experienced in regulatory affairs. These investments established a controlled, auditable baseline that underpins our current GMP operations and regulatory engagements.

2023 — Full vertical integration — intermediates to finished forms

Rraynex completed vertical integration across intermediates, API synthesis and multi-particulate finished-dosage manufacturing. This reduced handoffs, improved traceability, and allowed tighter process control — materially improving content uniformity, dissolution reproducibility, and yield across product families.

2024 — Pellet scale-up & GMP unit commissioning

Commissioned a dedicated GMP production unit for pellets and granules. Investments included process analytical technologies (PAT), automated coating and validated drying processes — reducing batch-to-batch variability and raising first-pass yields for multiparticulate products.

2025 — WHO-GMP certification & validated commercial capacity

Achieved WHO-GMP facility certification and validated commercial capacity: 125 MT/month for pellets and 30 MT/month for granules. The company expanded registered product offerings and published stability programs and DMF-ready summaries to support global filing and regulatory confidence.

2026 — Global recognition & continued growth

Rraynex earned international recognition — ISO 9001, ISO 14001 and ISO 45001 — and featured in global exhibitions and industry press for rapid growth. The company surpassed 127 registered product dossiers, maintained robust stability data, and set strategic targets for further capacity and regulatory approvals.

Selected photos from our production floors, analytical labs and packaging lines — illustrating how processes and quality controls operate together.